Key result
Single periprocedural treatment with a STAT-1 decoy oligodeoxynucleotide significantly reduced vascular and interstitial cellular rejection scores by 85% and 70%, respectively, in mouse heart allografts 9 days post-transplantation.
Why the study?
Does STAT-1 dODN reduce cellular rejection in mouse heart transplants?
Population
Male mice undergoing heterotopic heart transplantation in allogeneic B10.A to C57BL/6 and syngeneic C57BL/6…
Comparison
STAT-1 decoy oligodeoxynucleotide 10 µM… vs Mutant control ODN or vehicle administered as a…
Design
Preclinical, assessed by an experienced pathologist blinded towards the…
Follow-up
9 days
Authors
Loading...
May attenuate rejection in preclinical models; hypothesis-generating and should not yet change clinical practice.
Does STAT-1 dODN reduce cellular rejection in mouse heart transplants?
Effect estimate: 85% and 70% reduction
p-value: p=<0.05
Single periprocedural treatment with a STAT-1 dODN effectively reduces cellular rejection and pro-inflammatory gene expression in a mouse model of heart transplantation.
Stojanović et al. (2009) studied Acute cellular rejection in heart transplantation. STAT-1 decoy oligodeoxynucleotide (dODN) vs. Mutant control ODN or vehicle was evaluated on Vascular and interstitial cellular rejection scores at 9 days (85% and 70% reduction, p=<0.05). Single periprocedural treatment with a STAT-1 decoy oligodeoxynucleotide significantly reduced vascular and interstitial cellular rejection scores by 85% and 70%, respectively, in mouse heart allografts 9 days post-transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: